Top

Published in:

01-04-2017 | Editorial

Regulated and Unregulated Clinical Trials of Stem Cell Therapies for Stroke

Authors: Michael G. Liska, Marci G. Crowley, Cesar V. Borlongan

Published in: Translational Stroke Research | Issue 2/2017

Excerpt

Stem cell therapies have been demonstrated in the laboratory as an effective option in treating a number of neurological disorders, including stroke. By targeting the subacute and chronic phases of stroke, stem cell therapies offer the advantage of extending the intervention window which has traditionally been oppressively small. Although substantial laboratory data support this therapeutic potential, transitioning stem cell treatments into approved clinical products has proven difficult. The reasons for this are many, including fundamental complications which have accompanied non-traditional pharmaceuticals such as difficulties in achieving treatment/dosing/cell type consensus and also the regulatory and legislative hindrances which have plagued stem cell advancement. Fortunately, translational lab-to-clinic research endeavors are being made in all of the abovementioned categories, allowing the initiation of limited clinical trials of stem cell therapies for stroke patients. …

Muotri AR, Gage FH. Generation of neuronal variability and complexity. Nature. 2006;441(7097):1087–93. doi:10.1038/nature04959.CrossRefPubMed

Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature. 2006;441(7097):1094–6. doi:10.1038/nature04960.CrossRefPubMed

Chen J, Venkat P, Zacharek A, Chopp M. Neurorestorative therapy for stroke. Front Hum Neurosci. 2014;8:382. doi:10.3389/fnhum.2014.00382.PubMedPubMedCentral

Boltze J, Lukomska B, Jolkkonen J, consortium M-I. Mesenchymal stromal cells in stroke: improvement of motor recovery or functional compensation? Journal of Cerebral Blood Flow and Metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2014;34(8):1420–1. doi:10.1038/jcbfm.2014.94.CrossRef

Borlongan CV. Age of PISCES: stem-cell clinical trials in stroke. Lancet. 2016;388(10046):736–8. doi:10.1016/S0140-6736(16)31259-4.CrossRefPubMed

Stroemer P, Patel S, Hope A, Oliveira C, Pollock K, Sinden J. The neural stem cell line CTX0E03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion. Neurorehabil Neural Repair. 2009;23(9):895–909. doi:10.1177/1545968309335978.CrossRefPubMed

Hara K, Yasuhara T, Maki M, Matsukawa N, Masuda T, Yu SJ, et al. Neural progenitor NT2N cell lines from teratocarcinoma for transplantation therapy in stroke. Prog Neurobiol. 2008;85(3):318–34. doi:10.1016/j.pneurobio.2008.04.005.CrossRefPubMed

Kaneko Y, Hayashi T, Yu S, Tajiri N, Bae EC, Solomita MA, et al. Human amniotic epithelial cells express melatonin receptor MT1, but not melatonin receptor MT2: a new perspective to neuroprotection. J Pineal Res. 2011;50(3):272–80. doi:10.1111/j.1600-079X.2010.00837.x.CrossRefPubMed

Liu SP, Fu RH, Wu DC, Hsu CY, Chang CH, Lee W, et al. Mouse-induced pluripotent stem cells generated under hypoxic conditions in the absence of viral infection and oncogenic factors and used for ischemic stroke therapy. Stem Cells Dev. 2014;23(4):421–33. doi:10.1089/scd.2013.0182.CrossRefPubMed

10.

Li Z, McKercher SR, Cui J, Nie Z, Soussou W, Roberts AJ, et al. Myocyte enhancer factor 2C as a neurogenic and antiapoptotic transcription factor in murine embryonic stem cells. The Journal of Neuroscience: the official journal of the Society for Neuroscience. 2008;28(26):6557–68. doi:10.1523/JNEUROSCI.0134-08.2008.CrossRef

11.

Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. Prog Neurobiol. 2011;95(2):213–28. doi:10.1016/j.pneurobio.2011.08.005.CrossRefPubMedPubMedCentral

12.

Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke; a journal of cerebral circulation. 2016;47(7):1817–24. doi:10.1161/STROKEAHA.116.012995.CrossRef

13.

Prasad K, Sharma A, Garg A, Mohanty S, Bhatnagar S, Johri S, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke; a journal of cerebral circulation. 2014;45(12):3618–24. doi:10.1161/STROKEAHA.114.007028.CrossRef

14.

Borlongan CV, Lind JG, Dillon-Carter O, Yu G, Hadman M, Cheng C, et al. Intracerebral xenografts of mouse bone marrow cells in adult rats facilitate restoration of cerebral blood flow and blood-brain barrier. Brain Res. 2004;1009(1–2):26–33. doi:10.1016/j.brainres.2004.02.050.CrossRefPubMed

15.

Acosta SA, Tajiri N, Hoover J, Kaneko Y, Borlongan CV. Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke. Stroke; a journal of cerebral circulation. 2015;46(9):2616–27. doi:10.1161/STROKEAHA.115.009854.CrossRefPubMedCentral

16.

Savitz SI, Cramer SC, Wechsler L, Consortium S. Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. Stroke; a journal of cerebral circulation. 2014;45(2):634–9. doi:10.1161/STROKEAHA.113.003379.CrossRef

17.

Savitz SI, Chopp M, Deans R, Carmichael T, Phinney D, Wechsler L, et al. Stem cell therapy as an emerging paradigm for stroke (STEPS) II. Stroke; a journal of cerebral circulation. 2011;42(3):825–9. doi:10.1161/STROKEAHA.110.601914.CrossRef

18.

Borlongan CV, Fournier C, Stahl CE, Yu G, Xu L, Matsukawa N, et al. Gene therapy, cell transplantation and stroke. Frontiers in bioscience: a journal and virtual library. 2006;11:1090–101.CrossRef

19.

Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev. 2009;30(3):204–13. doi:10.1210/er.2008-0031.CrossRefPubMedPubMedCentral

20.

Tang Y, Yasuhara T, Hara K, Matsukawa N, Maki M, Yu G, et al. Transplantation of bone marrow-derived stem cells: a promising therapy for stroke. Cell Transplant. 2007;16(2):159–69.PubMed

21.

Gnecchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol. 2009;482:281–94. doi:10.1007/978-1-59745-060-7_18.CrossRefPubMed

22.

Maria Ferri AL, Bersano A, Lisini D, Boncoraglio G, Frigerio S, Parati E. Mesenchymal stem cells for ischemic stroke: progress and possibilities. Curr Med Chem. 2016;23(16):1598–608.CrossRefPubMed

23.

Yasuhara T, Matsukawa N, Hara K, Maki M, Ali MM, Yu SJ, et al. Notch-induced rat and human bone marrow stromal cell grafts reduce ischemic cell loss and ameliorate behavioral deficits in chronic stroke animals. Stem Cells Dev. 2009;18(10):1501–14. doi:10.1089/scd.2009.0011.CrossRefPubMed

24.

Yasuhara T, Hara K, Maki M, Mays RW, Deans RJ, Hess DC, et al. Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. Journal of Cerebral Blood Flow and Metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2008;28(11):1804–10. doi:10.1038/jcbfm.2008.68.CrossRef

25.

Uchida H, Morita T, Niizuma K, Kushida Y, Kuroda Y, Wakao S, et al. Transplantation of unique subpopulation of fibroblasts, muse cells, ameliorates experimental stroke possibly via robust neuronal differentiation. Stem Cells. 2016;34(1):160–73. doi:10.1002/stem.2206.CrossRefPubMed

26.

Borlongan CV. Bone marrow stem cell mobilization in stroke: a ‘bonehead’ may be good after all! Leukemia. 2011;25(11):1674–86. doi:10.1038/leu.2011.167.CrossRefPubMedPubMedCentral

27.

Rowart P, Erpicum P, Detry O, Weekers L, Gregoire C, Lechanteur C, et al. Mesenchymal stromal cell therapy in ischemia/reperfusion injury. Journal of Immunology Research. 2015;2015:602597. doi:10.1155/2015/602597.CrossRefPubMedPubMedCentral

28.

Eckert MA, Vu Q, Xie K, Yu J, Liao W, Cramer SC, et al. Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. Journal of Cerebral Blood Flow and Metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2013;33(9):1322–34. doi:10.1038/jcbfm.2013.91.CrossRef

29.

Kocsis JD, Honmou O. Bone marrow stem cells in experimental stroke. Prog Brain Res. 2012;201:79–98. doi:10.1016/B978-0-444-59544-7.00005-6.CrossRefPubMed

30.

Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med. 2010;5(6):933–46. doi:10.2217/rme.10.72.CrossRefPubMedPubMedCentral

31.

van Velthoven CT, Gonzalez F, Vexler ZS, Ferriero DM. Stem cells for neonatal stroke—the future is here. Front Cell Neurosci. 2014;8:207. doi:10.3389/fncel.2014.00207.PubMedPubMedCentral

32.

Anderson JD, Johansson HJ, Graham CS, Vesterlund M, Pham MT, Bramlett CS, et al. Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling. Stem Cells. 2016;34(3):601–13. doi:10.1002/stem.2298.CrossRefPubMed

33.

Duffy GP, Ahsan T, O’Brien T, Barry F, Nerem RM. Bone marrow-derived mesenchymal stem cells promote angiogenic processes in a time- and dose-dependent manner in vitro. Tissue Eng A. 2009;15(9):2459–70. doi:10.1089/ten.TEA.2008.0341.CrossRef

34.

Xiong Y, Mahmood A, Chopp M. Angiogenesis, neurogenesis and brain recovery of function following injury. Curr Opin Investig Drugs. 2010;11(3):298–308.PubMedPubMedCentral

35.

Ishikawa H, Tajiri N, Shinozuka K, Vasconcellos J, Kaneko Y, Lee HJ, et al. Vasculogenesis in experimental stroke after human cerebral endothelial cell transplantation. Stroke; a journal of cerebral circulation. 2013;44(12):3473–81. doi:10.1161/STROKEAHA.113.001943.CrossRefPubMedCentral

36.

Schweizer S, Meisel A, Marschenz S. Epigenetic mechanisms in cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2013;33(9):1335–46. doi:10.1038/jcbfm.2013.93.CrossRef

37.

Puyal J, Ginet V, Clarke PG. Multiple interacting cell death mechanisms in the mediation of excitotoxicity and ischemic brain damage: a challenge for neuroprotection. Prog Neurobiol. 2013;105:24–48. doi:10.1016/j.pneurobio.2013.03.002.CrossRefPubMed

38.

Sozmen EG, Hinman JD, Carmichael ST. Models that matter: white matter stroke models. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. 2012;9(2):349–58. doi:10.1007/s13311-012-0106-0.CrossRef

39.

Kim SJ, Moon GJ, Chang WH, Kim YH, Bang OY, collaborators S. Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. Trials. 2013;14:317. doi:10.1186/1745-6215-14-317.CrossRefPubMedPubMedCentral

40.

Surder D, Radrizzani M, Turchetto L, Cicero VL, Soncin S, Muzzarelli S, et al. Combined delivery of bone marrow-derived mononuclear cells in chronic ischemic heart disease: rationale and study design. Clin Cardiol. 2013;36(8):435–41. doi:10.1002/clc.22148.CrossRefPubMed

41.

Prasad K, Mohanty S, Bhatia R, Srivastava MV, Garg A, Srivastava A, et al. Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study. Indian J Med Res. 2012;136(2):221–8.PubMedPubMedCentral

42.

Mackie AR, Losordo DW. CD34-positive stem cells: in the treatment of heart and vascular disease in human beings. Tex Heart Inst J. 2011;38(5):474–85.PubMedPubMedCentral

43.

Kalladka D, Sinden J, Pollock K, Haig C, McLean J, Smith W, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet. 2016;388(10046):787–96. doi:10.1016/S0140-6736(16)30513-X.CrossRefPubMed

44.

Savitz SI, Misra V, Kasam M, Juneja H, Cox Jr CS, Alderman S, et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011;70(1):59–69. doi:10.1002/ana.22458.CrossRefPubMed

45.

Banerjee S, Bentley P, Hamady M, Marley S, Davis J, Shlebak A, et al. Intra-arterial immunoselected CD34+ stem cells for acute ischemic stroke. Stem Cell Transl Med. 2014;3(11):1322–30. doi:10.5966/sctm.2013-0178.CrossRef

46.

Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57(6):874–82. doi:10.1002/ana.20501.CrossRefPubMed

47.

Pollock K, Stroemer P, Patel S, Stevanato L, Hope A, Miljan E, et al. A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp Neurol. 2006;199(1):143–55. doi:10.1016/j.expneurol.2005.12.011.CrossRefPubMed

48.

Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001;164(11):1612.PubMedPubMedCentral

49.

Stevanato L, Corteling RL, Stroemer P, Hope A, Heward J, Miljan EA, et al. c-MycERTAM transgene silencing in a genetically modified human neural stem cell line implanted into MCAo rodent brain. BMC Neurosci. 2009;10:86–98. doi:10.1186/1471-2202-10-86.CrossRefPubMedPubMedCentral

50.

Dao MA, Tate CC, Aizman I, McGrogan M, Case CC. Comparing the immunosuppressive potency of naive marrow stromal cells and Notch-transfected marrow stromal cells. J Neuroinflammation. 2011;8:133–47. doi:10.1186/1742-2094-8-133.CrossRefPubMedPubMedCentral

51.

Napoli E, Borlongan CV. Recent advances in stem cell-based therapeutics for stroke. Transl Stroke Res. 2016;7(6):452–7. doi:10.1007/s12975-016-0490-6.CrossRefPubMed

52.

Diamandis T, Borlongan CV. One, two, three steps toward cell therapy for stroke. Stroke; a journal of cerebral circulation. 2015;46(2):588–91. doi:10.1161/STROKEAHA.114.007105.CrossRef

53.

Borlongan CV, McWhirter C, Fultz-Carver C, Fitzgerald KT, Sanberg PR. The case for an ethics research consortium for emerging technologies: public perception of stem cell research and development. Technology and Innovation. 2010;12:21–8.CrossRefPubMedPubMedCentral

54.

Hyun I. Therapeutic hope, spiritual distress, and the problem of stem cell tourism. Cell Stem Cell. 2013;12(5):505–7. doi:10.1016/j.stem.2013.04.010.CrossRefPubMed

55.

McArdle A, Senarath-Yapa K, Walmsley GG, Hu M, Atashroo DA, Tevlin R, et al. The role of stem cells in aesthetic surgery: fact or fiction? Plast Reconstr Surg. 2014;134(2):193–200. doi:10.1097/PRS.0000000000000404.CrossRefPubMedPubMedCentral

56.

Ryan KA, Sanders AN, Wang DD, Levine AD. Tracking the rise of stem cell tourism. Regen Med. 2010;5(1):27–33. doi:10.2217/rme.09.70.CrossRefPubMed

57.

Turner L. US stem cell clinics, patient safety, and the FDA. Trends Mol Med. 2015;21(5):271–3. doi:10.1016/j.molmed.2015.02.008.CrossRefPubMed

58.

Ledford H. Boom in unproven cell therapies intensifies regulatory debate. Nature. 2016;537(7619):148. doi:10.1038/537148a.CrossRefPubMed

59.

Cyranoski D. Stem cells in Texas: cowboy culture. Nature. 2013;494(7436):166–8. doi:10.1038/494166a.CrossRefPubMed

60.

Brown C. Stem cell tourism poses risks. CMAJ. 2012;184(2):E121–2. doi:10.1503/cmaj.109-4073.CrossRefPubMedPubMedCentral

61.

McLean AK, Stewart C, Kerridge I. Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia. Stem Cell Research & Therapy. 2015;6:33. doi:10.1186/s13287-015-0047-810.1186/scrt543.CrossRef

62.

Cyranoski D. China’s stem-cell rules go unheeded. Nature. 2012;484(7393):149–50. doi:10.1038/484149a.CrossRefPubMed

63.

Rosemann A, Sleeboom-Faulkner M. New regulation for clinical stem cell research in China: expected impact and challenges for implementation. Regen Med. 2016;11(1):5–9. doi:10.2217/rme.15.80.CrossRefPubMed

64.

Mason A, Wright KB. Framing medical tourism: an examination of appeal, risk, convalescence, accreditation, and interactivity in medical tourism web sites. J Health Commun. 2011;16(2):163–77. doi:10.1080/10810730.2010.535105.CrossRefPubMed

65.

Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell. 2008;3(6):591–4. doi:10.1016/j.stem.2008.11.001.CrossRefPubMed

66.

Kamenova K, Reshef A, Caulfield T. Representations of stem cell clinics on Twitter. Stem Cell Rev. 2014;10(6):753–60. doi:10.1007/s12015-014-9534-z.CrossRefPubMed

67.

Robillard JM, Cabral E, Hennessey C, Kwon BK, Illes J. Fueling hope: stem cells in social media. Stem Cell Rev. 2015;11(4):540–6. doi:10.1007/s12015-015-9591-y.CrossRefPubMed

68.

Lunt N, Hardey M, Mannion R. Nip, tuck and click: medical tourism and the emergence of web-based health information. The Open Medical Informatics Journal. 2010;4:1–11. doi:10.2174/1874431101004010001.CrossRefPubMedPubMedCentral

69.

Wagle S. Web-based medical facilitators in medical tourism: the third party in decision-making. Indian Journal of Medical Ethics. 2013;10(1):28–33.PubMed

70.

Berkowitz AL, Miller MB, Mir SA, Cagney D, Chavakula V, Guleria I, et al. Glioproliferative lesion of the spinal cord as a complication of “stem-cell tourism”. N Engl J Med. 2016;375(2):196–8. doi:10.1056/NEJMc1600188.CrossRefPubMed

71.

Cyranoski D. Strange lesions after stem-cell therapy. Nature. 2010;465(7301):997. doi:10.1038/465997a.CrossRefPubMed

72.

Thirabanjasak D, Tantiwongse K, Thorner PS. Angiomyeloproliferative lesions following autologous stem cell therapy. Journal of the American Society of Nephrology: JASN. 2010;21(7):1218–22. doi:10.1681/ASN.2009111156.CrossRefPubMedPubMedCentral

73.

Master Z, Robertson K, Frederick D, Rachul C, Caulfield T. Stem cell tourism and public education: the missing elements. Cell Stem Cell. 2014;15(3):267–70. doi:10.1016/j.stem.2014.08.009.CrossRefPubMed

74.

Tsou A. Ethical considerations when counseling patients about stem cell tourism. Continuum. 2015;21(1 Spinal Cord Disorders):201–5. doi:10.1212/01.CON.0000461094.76563.be.PubMed

75.

Ploughman M, Austin MW, Glynn L, Corbett D. The effects of poststroke aerobic exercise on neuroplasticity: a systematic review of animal and clinical studies. Transl Stroke Res. 2015;6(1):13–28. doi:10.1007/s12975-014-0357-7.CrossRefPubMed

76.

Eissler LA, Casken J. Seeking health care through international medical tourism. Journal of Nursing Scholarship: an official publication of Sigma Theta Tau International Honor Society of Nursing. 2013;45(2):177–84. doi:10.1111/jnu.12014.CrossRef

77.

Stem cell therapies: opportunities for ensuring the quality and safety of clinical offerings—summary of a joint workshop. Washington (DC) 2014.

78.

Merali Z, Leung J, Mikulis D, Silver F, Kassner A. Longitudinal assessment of imatinib’s effect on the blood-brain barrier after ischemia/reperfusion injury with permeability MRI. Transl Stroke Res. 2015;6(1):39–49. doi:10.1007/s12975-014-0358-6.CrossRefPubMed

79.

Zhu W, Casper A, Libal NL, Murphy SJ, Bodhankar S, Offner H, et al. Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke. Transl Stroke Res. 2015;6(1):60–8. doi:10.1007/s12975-014-0373-7.CrossRefPubMed

80.

Khan MB, Hoda MN, Vaibhav K, Giri S, Wang P, Waller JL, et al. Remote ischemic postconditioning: harnessing endogenous protection in a murine model of vascular cognitive impairment. Transl Stroke Res. 2015;6(1):69–77. doi:10.1007/s12975-014-0374-6.CrossRefPubMed

81.

Kandadai MA, Meunier JM, Hart K, Holland CK, Shaw GJ. Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis. Transl Stroke Res. 2015;6(1):78–87. doi:10.1007/s12975-014-0376-4.CrossRefPubMed

82.

Shi Y, Leak RK, Keep RF, Chen J. Translational stroke research on blood-brain barrier damage: challenges, perspectives, and goals. Transl Stroke Res. 2016;7(2):89–92. doi:10.1007/s12975-016-0447-9.CrossRefPubMed

83.

Lioutas VA, Alfaro-Martinez F, Bedoya F, Chung CC, Pimentel DA, Novak V. Intranasal insulin and insulin-like growth factor 1 as neuroprotectants in acute ischemic stroke. Transl Stroke Res. 2015;6(4):264–75. doi:10.1007/s12975-015-0409-7.CrossRefPubMedPubMedCentral

84.

Morihara R, Kono S, Sato K, Hishikawa N, Ohta Y, Yamashita T, et al. Thrombolysis with low-dose tissue plasminogen activator 3-4.5 h after acute ischemic stroke in five hospital groups in Japan. Transl Stroke Res. 2016;7(2):111–9. doi:10.1007/s12975-016-0448-8.CrossRefPubMed

85.

Reuter B, Rodemer C, Grudzenski S, Meairs S, Bugert P, Hennerici MG, et al. Effect of simvastatin on MMPs and TIMPs in human brain endothelial cells and experimental stroke. Transl Stroke Res. 2015;6(2):156–9. doi:10.1007/s12975-014-0381-7.CrossRefPubMed

86.

Soliman S, Ishrat T, Fouda AY, Patel A, Pillai B, Fagan SC. Sequential therapy with minocycline and candesartan improves long-term recovery after experimental stroke. Transl Stroke Res. 2015;6(4):309–22. doi:10.1007/s12975-015-0408-8.CrossRefPubMedPubMedCentral

87.

Ergul A, Hafez S, Fouda A, Fagan SC. Impact of comorbidities on acute injury and recovery in preclinical stroke research: focus on hypertension and diabetes. Transl Stroke Res. 2016;7(4):248–60. doi:10.1007/s12975-016-0464-8.CrossRefPubMed

88.

Hasegawa Y, Nakagawa T, Uekawa K, Ma M, Lin B, Kusaka H, et al. Therapy with the combination of amlodipine and irbesartan has persistent preventative effects on stroke onset associated with BDNF preservation on cerebral vessels in hypertensive rats. Transl Stroke Res. 2016;7(1):79–87. doi:10.1007/s12975-014-0383-5.CrossRefPubMed

89.

McCann SK, Cramond F, Macleod MR, Sena ES. Systematic review and meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke: an update. Transl Stroke Res. 2016;7(5):395–406. doi:10.1007/s12975-016-0489-z.CrossRefPubMedPubMedCentral

90.

Sun N, Keep RF, Hua Y, Xi G. Critical role of the sphingolipid pathway in stroke: a review of current utility and potential therapeutic targets. Transl Stroke Res. 2016;7(5):420–38. doi:10.1007/s12975-016-0477-3.CrossRefPubMed

91.

Suzuki H, Shiba M, Nakatsuka Y, Nakano F, Nishikawa H. Higher cerebrospinal fluid pH may contribute to the development of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Transl Stroke Res. 2016; doi:10.1007/s12975-016-0500-8.PubMed

92.

Yigitkanli K, Zheng Y, Pekcec A, Lo EH, van Leyen K. Increased 12/15-lipoxygenase leads to widespread brain injury following global cerebral ischemia. Transl Stroke Res. 2016; doi:10.1007/s12975-016-0509-z.PubMed

Title: Regulated and Unregulated Clinical Trials of Stem Cell Therapies for Stroke
Authors: Michael G. Liska
Marci G. Crowley
Cesar V. Borlongan
Publication date: 01-04-2017
Publisher: Springer US
Published in: Translational Stroke Research / Issue 2/2017
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-017-0522-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Regulated and Unregulated Clinical Trials of Stem Cell Therapies for Stroke

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2017

Induction of Perivascular Neural Stem Cells and Possible Contribution to Neurogenesis Following Transient Brain Ischemia/Reperfusion Injury

Association Between Dehydration and Short-Term Risk of Ischemic Stroke in Patients with Atrial Fibrillation

Role of Glibenclamide in Brain Injury After Intracerebral Hemorrhage

Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity

Early Erythrolysis in the Hematoma After Experimental Intracerebral Hemorrhage

Increased 12/15-Lipoxygenase Leads to Widespread Brain Injury Following Global Cerebral Ischemia